Insmed | INSM - Pre Tax Profit


Insmed reported $-162.1M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Novartis USD 3.84B 1.33B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026